Site Editor

Rebecca Olin, MD, MS


Using Patient-Reported Data to Predict Survival in AML

By: Celeste L. Dixon
Posted: Wednesday, July 1, 2020

According to the results of a recent study of patient-reported outcome data in patients with acute myeloid leukemia (AML), collecting these data systematically in routine practice may yield prognostic value in predicting overall survival, stated John Peipert, MD, of Northwestern University Feinberg School of Medicine, Chicago, and colleagues. Using a pool of 317 patients unfit for intensive therapy, the team found a two-point difference in the Physical Wellbeing Scale (PWS) component of the Functional Assessment of Cancer Therapy–Leukemia (FACT-Leu). This was associated with a 9% decline in overall survival. The investigators presented their work during the ASCO20 Virtual Scientific Program (Abstract 7532).

The findings add to the scant literature about “the prognostic value of patient-reported outcomes in patients with hematologic malignancies,” although it’s known that patient-reported outcomes help predict overall survival in populations with solid cancers, stated the researchers. They utilized Cox proportional hazard models to find that the FACT-Leu Total scale, as well as its component Trial Outcome Index (TOI), were significant prognostic factors for overall survival, but the PWS was the most significant. The P values for the FACT-Leu Total (5-point change in patient-reported outcome), TOI (4-point change), and PWS (2-point change) were .02, .03, and .002, respectively.

“These results may indicate patient-reported outcomes’ value as stratification factors in trials with AML patients,” concluded Dr. Peipert and colleagues. They added that the results were adjusted for many factors, ranging from arrhythmia and age to psychiatric disturbances.

Disclosure: The study authors’ disclosure information can be found at

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.